Global Transplantation COVID Report March 2020

Ahn, Chanwoo; Amer, Hala; Anglicheau, Dany; Ascher, N. L.; Baan, Carla C.; Battsetset, G; Bat-Ireedui, B; Berney, Thierry; Betjes, M.; Bichu, Shrirang; Birn, Henrik; Brennan, David M.; Bromberg, Jonathan S.; Caillard, Sophie; Cannon, Robert M.; Cantarovich, Marcelo; Chan, Albert; Chen, Z S; Chapman, Jeremy R.; Cole, Edward; Cross, Nathan M.; Durand, Francesca T.; Egawa, Hiroshi; Emond, Jean C.; Farrero, Marta; Friend, P; Geissler, Edward K.; Ha, jung woo; Haberal, Mehmet; Henderson, Macey L.; Hesselink, Dennis A.; Humar, Abhinav; Jassem, Wayel; Jeong, Jinho; Kaplan, Barry; Kee, Terence; Kim, Seungyeon; Kumar, Deepali; Legendre, Christophe; Man, Kenneth K C; Moulin, Anne‐Marie; Muller, Elmi; Munkhbat, R; Od-Erdene, L; Perrin, Peggy; Rela, Munipraveena; Tanabe, Katsuyuki; Silva, H Tedesco; Tinckam, K T; Tullius, Stefan G.; Wong, Gregory

doi:10.1097/tp.0000000000003258

Cited by 89 publications

(141 citation statements)

References 0 publications

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…The first case of corona virus disease 2019 (COVID- 19) was diagnosed in December 2019 in Wuhan, China [1][2][3]. Since then, this novel infectious disease, which is caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has grown into a pandemic with over 4 million infected individuals worldwide (https://who.sprinklr.com/; accessed May 14th, 2020) [1][2][3]. Various compounds with presumed antiviral activity are now being tested in clinical trials, but at present there is no demonstrated effective therapy other than supportive care [4][5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID‐19 in solid organ transplant recipients: a single‐center experience

et al. 2020

View full text Add to dashboard Cite

Summary Solid organ transplant (SOT) recipients may be at risk for severe COVID‐19. Data on the clinical course of COVID‐19 in immunosuppressed patients are limited, and the effective treatment strategy for these patients is unknown. We describe our institutional experience with COVID‐19 in SOT. Demographic, clinical, and treatment data were extracted from the electronic patient files. A total of 23 SOT transplant recipients suffering from COVID‐19 were identified (n = 3 heart; n = 15 kidney; n = 1 kidney‐after‐heart; n = 3 lung, and n = 1 liver transplant recipient). The presenting symptoms were similar to nonimmunocompromised patients. Eighty‐three percent (19/23) of the patients required hospitalization, but only two of these were transferred to the intensive care unit. Five patients died from COVID‐19; all had high Clinical Frailty Scores. In four of these patients, mechanical ventilation was deemed futile. In 57% of patients, the immunosuppressive therapy was not changed and only three patients were treated with chloroquine. Most patients recovered without experimental antiviral therapy. Modification of the immunosuppressive regimen alone could be a therapeutic option for SOT recipients suffering from moderate to severe COVID‐19. Pre‐existent frailty is associated with death from COVID‐19.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

COVID‐19 in solid organ transplant recipients: a single‐center experience

et al. 2020

View full text Add to dashboard Cite

show abstract

“…1 Measures imposed in many countries, including the UK have helped to reduce the number of new patients for health systems to cope. 2 Managing patients with COVID-19 is currently a major challenge in many countries, as the pathophysiology of COVID-19 is not fully understood and the treatment, is mainly supportive as evidence for specific therapies is yet to be established. 3 The host immune response as determined by the innate and adaptive systems appears to be both the determinant of COVID-19 resolution, as well as the severity of the inflammatory response that results in SARS and death.…”

Section: Introductionmentioning

confidence: 99%

“…3 The host immune response as determined by the innate and adaptive systems appears to be both the determinant of COVID-19 resolution, as well as the severity of the inflammatory response that results in SARS and death. 2,4 As a consequence, immunocompromised individuals have been classified as a COVID-19 high-risk group.…”

Section: Introductionmentioning

confidence: 99%

Low prevalence and disease severity of COVID‐19 in post‐liver transplant recipients—A single centre experience

Verma

Khorsandi

Dolcet

et al. 2020

Liver International

View full text Add to dashboard Cite

show abstract

“…The coronavirus disease 2019 (COVID-19) pandemic has led to unique challenges in solid organ transplantation as centers balance the risk of caring for immunosuppressed patients with the best timing and urgency of transplantation. Insufficient knowledge about COVID-19 and the potential risks of COVID-19 for transplant donors and recipients are limiting organ transplantation as well as research in transplantation [ 1 – 3 ]. However, transplantation is essential for lifesaving transplants of heart, lung, or liver and for deceased donor kidney transplantations (KT) in candidates with a lack of dialysis access or who are highly sensitized [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

General Approach to the Clinical Care of Solid Organ Transplant Recipients with COVID-19 Infection

2020

View full text Add to dashboard Cite

Purpose of Review Insufficient knowledge about COVID-19 and the potential risks of COVID-19 are limiting organ transplantation in wait-listed candidates and deferring essential health care in solid organ transplant recipients. In this review, we expand the understanding and present an overview of the optimized management of COVID-19 in solid organ transplant recipients. Recent Findings Transplant recipients are at an increased risk of severe COVID-19. The unique characteristics of transplant recipients can make it more difficult to identify COVID-19 . Based on the COVID-19 data to date and our experience, we present testing, management, and prevention methods for COVID-19. Comprehensive diagnostic tests should be performed to determine disease severity, phase of illness, and identify other comorbidities in transplant recipients diagnosed with COVID-19. Outpatients should receive education for preventative measures and optimal health care delivery minimizing potential infectious exposures. Multidisciplinary interventions should be provided to hospitalized transplant recipients for COVID-19 because of the complexity of caring for transplant recipients. Summary Transplant recipients should strictly adhere to infection prevention measures. Understanding of the transplant specific pathophysiology and development of effective treatment strategies for COVID-19 should be prioritized.

show abstract

Global Transplantation COVID Report March 2020

Cited by 89 publications

References 0 publications

COVID‐19 in solid organ transplant recipients: a single‐center experience

COVID‐19 in solid organ transplant recipients: a single‐center experience

Low prevalence and disease severity of COVID‐19 in post‐liver transplant recipients—A single centre experience

General Approach to the Clinical Care of Solid Organ Transplant Recipients with COVID-19 Infection

Contact Info

Product

Resources

About